• A case of anti-p200 pemphigoid after COVID-19 vaccination
• A case of bullous pemphigoid associated with psoriasis showing no tissue-bound immunoglobulin G on the inflamed skin
• A case of bullous pemphigoid complicated by mucosal lesions due to mucosal-dominant pemphigus vulgaris: analyzing the pathogenicity of anti-desmoglein 3 antibodies using a bead aggregation assay
• A case of immunoglobulin G4-related kidney disease manifesting after dipeptidyl peptidase-4 inhibitor treatment
• A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis
• A comprehensive analysis on the safety of two biologics dupilumab and omalizumab
• A rare case of cicatricial pemphigoid confined to the scalp with associated photodamage
• A rare case report of bullous pemphigoid caused by paclitaxel treatment for endometrial cancer
• A retrospective analysis of patient-reported physical and psychological stressors as trigger factors in autoimmune bullous disease
• A Retrospective Comparison of Diagnostic Tools of Bullous Pemphigoid for Elderly Patients
• Absence of Epidermal Antibodies in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Patients but Beware of Single Positive Results
• Acute myeloid leukemia with paraneoplastic pemphigus successfully treated with a personalized antileukemic and immunosuppressive strategy
• Acute photoallergic contact dermatitis from diclofenac mimicking bullous pemphigoid
• An Urticarial and Acral Manifestation of Bullous Pemphigoid After Vildagliptin Therapy: A Case Report
• Anti-IL-17 monoclonal antibodies and bullous pemphigoid: treatment or causal agents? A case series and review of the literature
• Assessing the Application of Large Language Models in Generating Dermatologic Patient Education Materials According to Reading Level: Qualitative Study
• Association of bullous pemphigoid and Grover disease induced by immune checkpoint therapy
• Association of Dipeptidiyl Peptidase-4 Inhibitors and Bullose Pemphigoid: A Report of Four Cases
• Association of recalcitrant scabies infestation and bullous pemphigoid in an infant
• Atezolizumab-Induced Type 1 Diabetic Ketoacidosis in a Patient With Small Cell Lung Cancer and Pre-existing Type 2 Diabetes Mellitus
• Atypical Presentation of Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) in a Patient on Pembrolizumab: A Case Report
• Autoimmune Dermatopathies of Horses
• Bullous pemphigoid and lichen planus pemphigoides in monozygotic twins with a long-standing history of psoriasis
• Bullous pemphigoid associated with cutaneous adnexal carcinoma
• Bullous pemphigoid in infancy
• Bullous pemphigoid induced by camrelizumab
• Bullous pemphigoid successfully treated with dupilumab
• Case of Bullous Pemphigoid Masquerading as Adult-Onset Atopic Dermatitis
• Case series of cutaneous myiasis in neglected cases of autoimmune bullous disorders
• Causal associations between both psoriasis and psoriatic arthritis and multiple autoimmune diseases: a bidirectional two-sample Mendelian randomization study
• Clinical and demographic characteristics of mucous membrane pemphigoid in India: A retrospective analysis
• Clinical and immunoserological characteristics of anti-p200 pemphigoid: Comparisons of patients with epitope spreading and non-epitope spreading
• Clinical management of bullous pemphigoid-The importance of cytology in diagnosis
• Comparing the risk of death, major adverse cardiac events, and relapse in bullous pemphigoid patients treated with systemic or topical corticosteroids
• Correction to: Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
• Cutaneous manifestations associated with COVID-19 infection at a university hospital in eastern China
• Cyclosporine for Recalcitrant Bullous Pemphigoid Induced by Nivolumab Therapy for Malignant Melanoma
• Demographic Data and Trends in Use of Amniotic Membrane Transplant During the Past Decade at a Tertiary Eye Center
• Development of bullous pemphigoid with autoantibodies against full-length BP180 following COVID-19 infection
• Development of bullous systemic lupus erythematosus in patient treated with NB-UVB: A case report and comprehensive review of the literature
• Diacron-Reactive Oxygen Metabolites Levels Are Initially Elevated in Patients with Bullous Pemphigoid
• Diagnostic challenge: Juvenile bullous pemphigoid with a negative BP180 ELISA
• Diagnostic Utility of Direct Immunofluorescence on Paraffin-Embedded Skin Biopsy Samples for the Diagnosis of Autoimmune Vesiculobullous Lesions
• Epidemiological Insights into Autoimmune Bullous Diseases in China: A Comprehensive Analysis
• Erfolgreiche Behandlung eines Anti‐P200‐Pemphigoids in Verbindung mit Plaque‐Psoriasis mit Guselkumab: Successful treatment with guselkumab of anti‐p200 pemphigoid associated with plaque psoriasis
• Evaluation of chronic pruritus and associated skin findings in patients with diabetes mellitus
• Facetten des Pemphigoids: Lokalisiert vernarbendes Pemphigoid Typ Brunsting‐Perry
• Fast itch relief during dupilumab predicts clinical efficacy in bullous pemphigoid, a retrospective cohort study
• FcRn inhibition reduces bullous pemphigoid anti-basement membrane zone IgG deposition and blistering in 3D human skin equivalents
• Frequency and Correlation of Peripheral and Tissue Eosinophilia with Clinical Manifestations in Patients with Bullous Pemphigoid
• Functional decline among bullous pemphigoid patients: A retrospective monocentric cohort study
• Hickam versus Ockham: atopic dermatitis and bullous pemphigoid or pemphigoid nodularis? Dupilumab solves the problem
• High serum total IgE levels correlate with urticarial lesions and IgE deposition in perilesional skin of bullous pemphigoid patients: An observational study
• HLA alleles associated to susceptibility to gliptin-associated bullous pemphigoid in Italian patients
• Hospitalization and mortality in Asian autoimmune bullous dermatosis patients: A 17-year retrospective study
• Immune Landscape within Cutaneous Lesions of Human Bullous Pemphigoid
• Impact of insurance status on treatment choice and hospitalization rates in bullous pemphigoid patients: a retrospective cross-sectional analysis
• Infantile Bullous Pemphigoid: A Case Report
• Inhibition of interferon gamma impairs induction of experimental epidermolysis bullosa acquisita
• Interest of therapeutic plasmapheresis in a chronic hemodialysis patient with severe bullous pemphigoid
• JAAD Game Changers: "Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up"
• Lichen planus pemphigoides with predominant mucous membrane involvement: a series of 12 patients and a literature review
• Localized bullous pemphigoid triggered by a closed wrist fracture
• Lymphocytic infiltration as a marker of disease severity in patients with bullous pemphigoid-A case series
• Multirefractory bullous pemphigoid, psoriasis and psoriatic arthritis successfully treated with guselkumab
• Neonatal Fc Receptor Inhibition Reduces Bullous Pemphigoid Anti-Basement Membrane Zone IgG Deposition and Blistering in 3-Dimensional Human Skin Equivalents
• New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review
• New-onset or flare-up of bullous pemphigoid associated with COVID-19 vaccines: a systematic review of case report and case series studies
• Occurrence of Bullous Pemphigoid in a Longstanding Case of Rheumatoid Arthritis in an Indian Patient: A Rare Association
• Omalizumab in the treatment of bullous pemphigoid: A single-center series of 15 cases
• Paraneoplastic pemphigus with underlying Castleman's disease in a 16-year-old girl
• PD-1/PD-L1 Checkpoint Inhibition Associated Bullous Pemphigoid: A Propensity Matched Retrospective Cohort Study
• Pembrolizumab therapy in a patient with NSCLC and bullous pemphigoid: A case report
• Pembrolizumab-Induced Hypertrophic Lichenoid Dermatitis and Bullous Pemphigoid in One Patient
• Pemphigoid diseases in patients with end-stage kidney diseases: pathogenesis and treatment
• Perifollicular Melanocyte Regeneration in Bullous Pemphigoid
• Prevalence and clinical markers of herpes simplex virus infection in oral lesions of bullous pemphigoid
• Prevalence of tobacco use in patients with autoimmune blistering diseases: A nationwide, cross-sectional study
• Programmed death receptor-1 and programmed death ligand-1 checkpoint inhibition-associated bullous pemphigoid: a propensity-matched retrospective cohort study
• Radiotherapy-induced localized bullous pemphigoid with a favorable response to dupilumab
• Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature
• Reactivity against the BP180 ectodomain in patients with bullous pemphigoid, mucous membrane pemphigoid, multiple sclerosis and Parkinson disease
• Revisiting serum storage protocols: assessing the impact of temperature variations on indirect immunofluorescence testing for pemphigus and bullous pemphigoid
• Sequential occurrence of primary cutaneous indeterminate cell histiocytosis after oesophageal cancer and subsequent bullous pemphigoid: a case report
• Serum Biomarkers in Bullous Pemphigoid: A Systematic Review
• Severe bullous pemphigoid in a 4-month-old infant
• Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease
• Skin-brain axis in Alzheimer's disease - Pathologic, diagnostic, and therapeutic implications: A Hypothetical Review
• Skin-Related Adverse Reactions Induced by Oral Antidiabetic Drugs-A Review of Literature and Case Reports
• Spesolimab in the Management of Generalized Pustular Psoriasis With Concurrent Bullous Pemphigoid and Psoriasis
• State-of-the-art diagnosis of autoimmune blistering diseases
• Successful dupilumab treatment in bullous pemphigoid complicated with subacute hematogenous disseminated tuberculosis: A case report
• Successful treatment of infantile refractory bullous pemphigoid with baricitinib
• Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments
• The cardiovascular risk in bullous pemphigoid: Insights from a population-based study
• The Safety of Topical versus Oral Steroids in Bullous Pemphigoid: Considerations for Retrospective Analyses
• The Skin and Lewy Body Disease
• Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients
• Unique Scabies Presentation in a Patient with Bullous Pemphigoid
• Update: Protective and risk factors for Parkinson disease